valrubicin (AD 32)

Also Known As:

AD 32; (2S-cis)-pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; AD-32; N-trifluoroacetyladriamycin 14-valerate; NSC-246131; Valstar; Valtaxin; adriamycin, trifluoroacetyl-, 14-valerate

Networked: 74 relevant articles (3 outcomes, 19 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Rosada, Cecilia: 4 articles (12/2015 - 02/2010)
2.	Stenderup, Karin: 4 articles (12/2015 - 02/2010)
3.	Lacko, Andras G: 3 articles (01/2017 - 01/2012)
4.	de Darkó, Elisabeth: 3 articles (10/2013 - 02/2010)
5.	Wajsman, Z: 3 articles (09/2001 - 03/2000)
6.	Raut, Sangram: 2 articles (01/2017 - 02/2016)
7.	Jarow, Jonathan: 2 articles (04/2016 - 01/2015)
8.	Sabnis, Nirupama: 2 articles (02/2016 - 01/2012)
9.	Andersen, Stine M: 2 articles (12/2015 - 08/2010)
10.	Dam, Tomas N: 2 articles (12/2015 - 08/2010)

Related Diseases

1.	Neoplasms (Cancer) 08/01/2010 - "This study demonstrated that topical application of valrubicin has a beneficial effect in treating developing skin tumors." 04/01/1996 - "Phase 1 trial of intraperitoneal AD-32 in gynecologic malignancies." 01/01/2012 - "The data obtained demonstrated effective receptor- mediated uptake of AD-32 from the rHDL nanocarriers by PC-3 and SKOV-3 cancer cells via a targeted drug-delivery process. " 01/01/2012 - "Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles." 08/01/2010 - "Topical application of valrubicin has a beneficial effect on developing skin tumors."
2.	Urinary Bladder Neoplasms (Bladder Cancer) 06/01/2001 - "Randomised studies of intravesical valrubicin for the treatment of superficial bladder cancer are ongoing." 06/01/2001 - "The use of valrubicin for the chemoresection of superficial bladder cancer -- a marker lesion study." 04/27/2016 - "Disappointingly, there has been only one new FDA approved drug (Valrubicin) in any bladder cancer disease state since 1998. " 08/01/2010 - "In its current liquid formulation (Valstar; Indevus Pharmaceuticals, Lexington, MA), it is approved solely for the treatment of bladder cancer. " 08/01/2000 - "Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer."
3.	Leukemia L1210 01/01/1978 - "As with adriamycin, AD 32 was ineffective on ic transplanted L1210 leukemia." 05/01/1975 - "In the L1210 leukemia system, AD 32 at several dosages consistently and reproducibly effected an increase in lifespan in excess of 445%, with a high percentage of 60+-day survivors compared to adriamycin (+42 to +54% ILS; no 30-day survivors). " 01/01/1978 - "In all conditions tested, ie, ascitic and disseminated L1210 leukemia, ascitic LSTRA lymphoma, and advanced Lewis lung carcinoma, AD 32 was significantly more effective in terms of lifespan prolongation and induction of cures than optimal adriamycin treatments. " 05/01/1979 - "Golden hamsters received Adriamycin (ADR), detorubicin (DTR), AD-32, or aclacinomycin (ACM) three times weekly at doses extrapolated from optimal doses in L1210 leukemia. " 01/01/1978 - "The antitumor activity and toxicity of N-trifluoroacetyladriamycin-14-valerate (AD 32) dissolved in 10% Tween 80 in distilled water were compared to those of adriamycin dissolved in distilled water in 10% Tween 80 in distilled water, in mice bearing L1210 leukemia, P388 leukemia, Gross leukemia, and solid Sarcoma 180. "
4.	Lewis Lung Carcinoma 08/01/1980 - "Peak levels, areas under the curve, and beta-half-lives of AD 32 and AD 41 after an iv injection of 80 mg/kg of AD 32 to Lewis lung carcinoma-bearing mice are presented. " 06/11/1979 - "Pharmacokinetics of AD 32 and AD 41 are reported in blood and some tissues of mice bearing Lewis Lung carcinoma." 01/01/1978 - "In all conditions tested, ie, ascitic and disseminated L1210 leukemia, ascitic LSTRA lymphoma, and advanced Lewis lung carcinoma, AD 32 was significantly more effective in terms of lifespan prolongation and induction of cures than optimal adriamycin treatments. "
5.	Lymphoma (Lymphomas) 01/01/1978 - "In all conditions tested, ie, ascitic and disseminated L1210 leukemia, ascitic LSTRA lymphoma, and advanced Lewis lung carcinoma, AD 32 was significantly more effective in terms of lifespan prolongation and induction of cures than optimal adriamycin treatments. "

Related Drugs and Biologics

1.	Doxorubicin (Adriamycin)
2.	Daunorubicin (Cerubidine)
3.	Anthracyclines
4.	Gemcitabine
5.	Interferons
6.	Mitomycin (Mitomycin-C)
7.	Epirubicin (Ellence)
8.	Thiotepa (Triethylenethiophosphoramide)
9.	HDL Lipoproteins
10.	Antineoplastic Agents (Antineoplastics)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Heterologous Transplantation (Xenotransplantation)
4.	Cystectomy
5.	Salvage Therapy